GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Indaptus Therapeutics Inc (NAS:INDP) » Definitions » Current Ratio

Indaptus Therapeutics (Indaptus Therapeutics) Current Ratio

: 5.05 (As of Dec. 2023)
View and export this data going back to 2021. Start your Free Trial

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Indaptus Therapeutics's current ratio for the quarter that ended in Dec. 2023 was 5.05.

Indaptus Therapeutics has a current ratio of 5.05. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Indaptus Therapeutics's Current Ratio or its related term are showing as below:

INDP' s Current Ratio Range Over the Past 10 Years
Min: 0.86   Med: 6.5   Max: 8.77
Current: 5.05

During the past 4 years, Indaptus Therapeutics's highest Current Ratio was 8.77. The lowest was 0.86. And the median was 6.50.

INDP's Current Ratio is ranked better than
60.58% of 1555 companies
in the Biotechnology industry
Industry Median: 3.82 vs INDP: 5.05

Indaptus Therapeutics Current Ratio Historical Data

The historical data trend for Indaptus Therapeutics's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Indaptus Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Current Ratio
0.86 8.77 7.94 5.05

Indaptus Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Current Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.94 12.16 9.45 7.12 5.05

Competitive Comparison

For the Biotechnology subindustry, Indaptus Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Indaptus Therapeutics Current Ratio Distribution

For the Biotechnology industry and Healthcare sector, Indaptus Therapeutics's Current Ratio distribution charts can be found below:

* The bar in red indicates where Indaptus Therapeutics's Current Ratio falls into.



Indaptus Therapeutics Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Indaptus Therapeutics's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=13.995/2.774
=5.05

Indaptus Therapeutics's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=13.995/2.774
=5.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Indaptus Therapeutics  (NAS:INDP) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Indaptus Therapeutics Current Ratio Related Terms

Thank you for viewing the detailed overview of Indaptus Therapeutics's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Indaptus Therapeutics (Indaptus Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
3 Columbus Circle, 15th Floor, New York, NY, USA, 10019
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma in standard pre-clinical models.
Executives
Glen R. Anderson 10 percent owner 3274 ROSS ROAD, PALO ALTO CA 94303
Roger J. Waltzman officer: Chief Medical Officer C/O JAGUAR ANIMAL HEALTH, INC., 201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105
Robert Martell director 4 MAGUIRE ROAD, LEXINGTON MA 02421
Boyan Vesselinov Litchev officer: Chief Medical Officer 13357 RUSSET LEAF LN., SAN DIEGO CA 92129
Jeffrey A Meckler director, officer: Chief Executive Officer 740 BROADWAY, 9TH FLOOR, NEW YORK NY 10003
Walt Addison Linscott officer: Chief Business Officer 1860 MONTREAL ROAD, TUCKER GA 30084
Michael James Newman director, 10 percent owner, officer: Chief Scientific Officer C/O INTEC PARENT, INC., 12 HARTOM ST., HAR HOTZVIM, JERUSALEM L3 9777512
Mark John Gilbert director 13731 NORTHWOOD RD., NW, SEATTLE WA 98177
Brian O'callaghan director 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Hoonmo Lee director, 10 percent owner C/O INTEC PARENT, INC., 12 HARTOM ST., HAR HOTZVIM, JERUSALEM L3 9777512
Anthony J Maddaluna director PFIZER INC. ATTN CORPORATE SECRETARY, 235 RAST 42ND STREET, NEW YORK NY 10017
William B Hayes director 231 MAPLE AVENUE, BURLINGTON NC 27215
Roger Pomerantz director 711 HARVEST HILL ROAD, CHALFONT PA 18914
Hila Karah director 9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
Nir Sassi officer: Chief Financial Officer 3 ELUL STREET, APT. 6, MODIIN L3 7176397

Indaptus Therapeutics (Indaptus Therapeutics) Headlines

From GuruFocus